6-甲基苯并[b]噻吩-2-羧酸 | 1467-86-3

• 物质功能分类: 医药中间体 - 杂环化合物 - 噻吩类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 中文名称: 6-甲基苯并[b]噻吩-2-羧酸
• 中文别名: 6-甲基苯并噻吩-2-甲酸；6-甲基苯并噻吩-2-羧酸
• 英文名称: 6-methyl-2-benzo[b]thiophenecarboxylic acid
• 英文别名: 6-methyl-benzo[b]thiophene-2-carboxylic acid；6-methylbenzo[b]thiophene-2-carboxylic acid；6-methyl-1-benzothiophene-2-carboxylic acid
• CAS: 1467-86-3
• 化学式: C₁₀H₈O₂S
• mdl: MFCD07377056
• 分子量: 192.238
• InChiKey: KQRBOHOKLNORTA-UHFFFAOYSA-N

物化性质

• 熔点：
  243-244°C
• 沸点：
  386.1±22.0 °C(Predicted)
• 密度：
  1.355±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  65.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  储存温度应控制在2-8°C，并需避光保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Methylbenzo[b]thiophene-2-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Methylbenzo[b]thiophene-2-carboxylic acid
CAS number: 1467-86-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H8O2S
Molecular weight: 192.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-甲基苯并[b]噻吩-2-羧酸 在 lithium aluminium tetrahydride 、 chromium trioxide pyridine 、 sodium hydride 作用下， 以 吡啶 、 乙醚 为溶剂， 反应 5.0h， 生成 6-methyl-2-styrylbenzothiophene
  参考文献：
  名称：

  Tominaga, Yoshinori; Pratap, Ram; Castle, Raymond N., Journal of Heterocyclic Chemistry, 1982, vol. 19, p. 871 - 877

  摘要：

  DOI：
• 作为产物：
  描述：

  3-氯-6-甲基-2-苯并噻吩甲酸 在 palladium on activated charcoal 、 氢气 、 sodium hydroxide 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 以90.6%的产率得到6-甲基苯并[b]噻吩-2-羧酸
  参考文献：
  名称：

  Process for the preparation of ibodutant (MEN15596) and related intermediates

  摘要：

  这项发明涉及一种用于合成下图所示的产品ibodutant的新型工艺，包括少量高产率步骤，涉及具有低环境影响的试剂和溶剂，其特点是将两部分化合物（3）和（4）耦合在一起，其中一个（3）是通过将6-甲基-2-苯并[b]噻吩羧酸（1）与1-氨基-α-α-环戊烷羧酸偶联并随后与噁唑酮环化合成的，而另一个化合物（4）则是通过对4-氨甲基哌啶（2）进行适当高选择性的官能化获得的。

  公开号：

  US08431684B2

文献信息

• DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS
  申请人：Connolly Peter J.

  公开号：US20120058986A1

  公开（公告）日：2012-03-08

  Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein Q and Z are defined herein.

  揭示了用于治疗各种疾病、综合症、症状和障碍的化合物、组合物和方法，包括疼痛。这些化合物由以下式（I）表示： 其中Q和Z在此处定义。
• OXOPIPERAZINE-AZETIDINE AMIDES AND OXODIAZEPINE-AZETIDINE AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS
  申请人：Connolly Peter J.

  公开号：US20120077797A1

  公开（公告）日：2012-03-29

  Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds, and enantiomers, diastereomers, and pharmaceutically acceptable salts thereof, are represented by Formula (Ia) and Formula (Ib) as follows: wherein Y, Z, and n are defined herein; and wherein Y b and Z b are as defined herein.

  本文披露了用于治疗各种疾病、综合症、状况和障碍，包括疼痛的化合物、组合物和方法。这些化合物及其对映体、二对映体和药学上可接受的盐由以下的化学式(Ia)和化学式(Ib)表示：其中Y、Z和n在此定义；以及其中Yband Zbare如此定义。
• [EN] GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS<br/>[FR] COMPOSÉS AMIDE DE QUINUCLIDINE À SUBSTITUANTS GÉMINAL, EN TANT QU'AGONISTES DES RÉCEPTEURS NICOTINIQUES DE L'ACÉTYLCHOLINE Α7
  申请人：FORUM PHARMACEUTICALS INC

  公开号：WO2016100184A1

  公开（公告）日：2016-06-23

  The present invention relates to novel geminal substituted quinuclidine amide compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of α7- nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

  本发明涉及新型的伏立康定酰胺化合物，以及相应的药物组合物，其适用于作为α7-nAChR的激动剂或部分激动剂，并且涉及制备这些化合物和组合物的方法，以及在维持、治疗和/或改善认知功能的方法中使用这些化合物和组合物，特别是将该化合物或组合物用于需要的患者的给药方法，例如患有认知缺陷和/或希望增强认知功能的患者，这些患者可能从中获益。
• Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same
  申请人：Man Hon-Wah

  公开号：US20110196150A1

  公开（公告）日：2011-08-11

  Provided are 4′-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

  提供了4'-芳基甲氧基异吲哚啉化合物，以及其药用盐、溶剂合物、包合物、立体异构体和前药。公开了这些化合物的使用方法和药物组合物。
• [EN] INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF<br/>[FR] INHIBITEURS DE LA KALLIKRÉINE PLASMATIQUE ET UTILISATIONS ASSOCIÉES
  申请人：DYAX CORP

  公开号：WO2019028362A1

  公开（公告）日：2019-02-07

  Provided herein are compounds that inhibit pKal, a serine protease whose activity is responsible for proteolytically cleaving kininogen and generating the potent vasodilator and pro-inflammatory peptide bradykinin, which can lead to painful and debilitating inflammatory attacks (e.g., edema). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating pKal-related diseases and disorders (e.g., edema) with the compounds in a subject, by administering the compounds and/or compositions described herein.

  本文提供了抑制pKal的化合物，pKal是一种丝氨酸蛋白酶，其活性负责蛋白酶解切激肽原并生成强效的血管舒张剂和促炎肽布雷金因，这可能导致疼痛和令人痛苦的炎症发作（例如水肿）。还提供了包含这些化合物的药物组合物和试剂盒，以及使用这些化合物在受试者中治疗pKal相关疾病和紊乱（例如水肿）的方法，通过给予本文所述的化合物和/或组合物。